144 related articles for article (PubMed ID: 31579984)
41. Bicalutamide versus flutamide in combination therapy.
Labrie F; Candas B
Urology; 1999 Mar; 53(3):662-3. PubMed ID: 10096411
[No Abstract] [Full Text] [Related]
42. Preliminary study with bicalutamide in heterosexual and homosexual patients with prostate cancer: a possible implication of androgens in male homosexual arousal.
Motofei IG; Rowland DL; Popa F; Kreienkamp D; Paunica S
BJU Int; 2011 Jul; 108(1):110-5. PubMed ID: 20955264
[TBL] [Abstract][Full Text] [Related]
43. Combined Oral Contraception and Bicalutamide in Polycystic Ovary Syndrome and Severe Hirsutism: A Double-Blind Randomized Controlled Trial.
Moretti C; Guccione L; Di Giacinto P; Simonelli I; Exacoustos C; Toscano V; Motta C; De Leo V; Petraglia F; Lenzi A
J Clin Endocrinol Metab; 2018 Mar; 103(3):824-838. PubMed ID: 29211888
[TBL] [Abstract][Full Text] [Related]
44. No long-term effects of hormonal therapy preceding brachytherapy on urinary function and health-related quality of life among prostate cancer patients.
Evers J; Kupper N; Kessing D; Davits R; Engelen A; Poortmans P; Mols F
Urology; 2010 Nov; 76(5):1150-6. PubMed ID: 20869105
[TBL] [Abstract][Full Text] [Related]
45. Adjuvant hormonal treatment - the bicalutamide early prostate cancer program.
Wirth MP; Hakenberg OW; Froehner M
Front Radiat Ther Oncol; 2008; 41():39-48. PubMed ID: 18544984
[TBL] [Abstract][Full Text] [Related]
46. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
[TBL] [Abstract][Full Text] [Related]
47. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
[TBL] [Abstract][Full Text] [Related]
48. Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.
Yano A; Kagawa M; Takeshita H; Okada Y; Morozumi M; Kawakami S
Int J Urol; 2017 Dec; 24(12):861-862. PubMed ID: 28895205
[No Abstract] [Full Text] [Related]
49. The third analysis of the bicalutamide Early Prostate Cancer programme.
Iversen P;
BJU Int; 2006 Mar; 97(3):438-9. PubMed ID: 16469002
[No Abstract] [Full Text] [Related]
50. Bicalutamide treatment for locally advanced prostate cancer.
Anderson J
Hosp Med; 2000 Sep; 61(9):660-3. PubMed ID: 11048610
[TBL] [Abstract][Full Text] [Related]
51. A case of male breast cancer in association with bicalutamide-induced gynaecomastia.
Chianakwalam CI; McCahy P; Griffiths NJ
Breast; 2005 Apr; 14(2):163-4. PubMed ID: 15767188
[No Abstract] [Full Text] [Related]
52. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
Sivko AV; Prokhorov AV
Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
[No Abstract] [Full Text] [Related]
53. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
[TBL] [Abstract][Full Text] [Related]
54. Bicalutamide (Casodex): The Critical Issues 1996. Proceedings of a meeting. Boston, Massachusetts, July 6-9, 1995.
Urology; 1996 Jan; 47(1A Suppl):1-96. PubMed ID: 8560672
[No Abstract] [Full Text] [Related]
55. Reduction of flutamide-induced alanine aminotransferase elevation after replacement by bicalutamide in a patient with N+ disease treated with maximal androgen blockade as a primary treatment.
Palmberg C; Kylmala T; Tammela T
Br J Urol; 1997 May; 79(5):808-9. PubMed ID: 9158528
[No Abstract] [Full Text] [Related]
56. Update on idiopathic hirsutism: diagnosis and treatment.
Erem C
Acta Clin Belg; 2013; 68(4):268-74. PubMed ID: 24455796
[TBL] [Abstract][Full Text] [Related]
57. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Nihoyannopoulos P; Kemp M; Hooper J; Rajkumar C
Clin Endocrinol (Oxf); 2008 Jan; 68(1):59-65. PubMed ID: 17692108
[TBL] [Abstract][Full Text] [Related]
58. Comment on "Bicalutamide Improves Minoxidil-Induced Hypertrichosis in Female Pattern Hair Loss: A Retrospective Review of 35 Patients".
Trüeb RM; Luu NC; Rezende HD
J Am Acad Dermatol; 2022 Jul; 87(1):e29-e30. PubMed ID: 35304167
[No Abstract] [Full Text] [Related]
59. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
[TBL] [Abstract][Full Text] [Related]
60. Excellent Response With Alpelisib and Bicalutamide for Advanced Salivary Duct Carcinoma With PIK3CA Mutation and High Androgen Receptor Expression-A Case Report.
Sheth H; Kumar P; Shreenivas A; Sambath J; Pragya R; Madre C; Athikari N; Khandare H; Peshattiwar V; Datar R; Limaye S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036229
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
